Fintel reports that on February 28, 2025, Stifel upgraded their outlook for Vital Farms (NasdaqGM:VITL) from Hold to Buy.

The life sciences industry experienced a dynamic year in 2024. As the public markets gained traction, IPO activity and venture investment saw ...

Rocket Lab USA Inc. shares tumbled in the wake of the company's fourth-quarter results Thursday, weighed down by weak outlook, although analyst firm KeyBanc Capital Markets believes the company's long ...

Stifel lowered the firm’s price target on Rocket Lab (RKLB) to $27 from $31 and keeps a Buy rating on the shares. The firm says a “solid” Q4 ...

Stifel (NYSE: SF), the official team naming partner of the Stifel U.S. Alpine Ski Team, is proud to celebrate the 100th career World Cup victory for Mikaela Shiffrin this past weekend as she captured ...

Italian payments group Nexi on Friday posted a 7% year-on-year rise in 2024 core profit to 1.86 billion euros ($1.93 billion) ...

Stifel Financial Corp. (NYSE: SF) today reported selected operating results for January 31, 2025 in an effort to provide timely information to investors on ...

(NYSE:AGL – Get Free Report) had its target price upped by stock analysts at Stifel Nicolaus from $2.00 to $3.00 in a note ...

Spin Master (TSE:TOY – Get Free Report) had its target price dropped by equities researchers at Stifel Nicolaus from C$45.00 ...

ST. LOUIS, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for ...

Stifel initiates Compass Pathways with a buy, highlighting psychedelics' therapeutic potential. Read more here.

Stifel analyst Mark Astrachan downgraded ARKO Corp (NASDAQ: ARKO) from Buy to Hold, reducing the price target to $7.5. ARKO's fourth-quarter results showed weaker-than-expected adjusted EBITDA and ...